Healio
FDA approves self-administered nasal spray for paroxysmal supraventricular tachycardia
Milestone Pharmaceuticals announced the FDA approval of prescription etripamil nasal spray for the treatment of acute ...
Fierce Pharma
Milestone wins 1st-ever FDA approval with green light for heart arrhythmia nasal spray
Clearing clinical and regulatory hurdles in the development of a fast-acting nasal spray for a heart condition has given ...
TCTMD
Etripamil Nasal Spray Gains FDA Approval for Acute Paroxysmal SVT
The self-administered treatment rapidly converts patients into sinus rhythm and may reduce trips to the hospital.
The American Journal of Managed Care
FDA Approves Intranasal Etripamil for Type of Arrhythmia
The FDA has approved intranasal etripamil (Cardamyst; Milestone Pharmaceuticals) for the acute treatment of paroxysmal supraventricular tachycardia (PSVT), making it the first self-administered, ...
Milestone Receives FDA Approval of CARDAMYST™ (etripamil) as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia (…
First FDA approved treatment in 30+ years for more than 2 million Americans with PSVT Novel nasal spray designed to rapidly ...
Milestone Wins FDA Approval For First Self-Use Nasal Spray For Sudden Fast Heartbeats
The FDA approved Milestone Pharmaceuticals' Cardamyst nasal spray for acute episodes of PSVT in adults. First treatment for ...